文献速递乳腺癌

CCTG辅助乳腺癌试验中基线BMI与体重变化的影响

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
PubMed 文献 · Ann Oncol · 2017-01-01

该分析纳入CCTG辅助乳腺癌化疗、内分泌治疗及曲妥珠单抗试验数据,主要考察5年界标时BMI变化对无乳腺癌间期的影响。结果显示,仅在绝经前/围绝经/绝经早期化疗试验中,较高基线BMI和BMI增加与更差结局相关;其他情况下BMI变化未影响结局或与更好结局相关。

要点

  • 绝经前/围绝经/绝经早期化疗试验中,基线BMI不影响任何终点,5年界标BMI增加对BCFI无显著影响(P=0.85)。
  • MA.12绝经前内分泌治疗中,较高基线BMI与1年BCFI更差相关(P=0.02),5年OS更差(P=0.01)。
  • 绝经后内分泌治疗试验中,基线BMI对任何终点均无显著影响,BMI变化对BCFI或DSS无影响。

核心结论

  • 较高基线BMI和BMI增加仅对绝经前/围绝经/绝经早期试验患者的结局产生负面影响,其余情况下BMI增加未影响结局或与更好结局相关。

研究设计与样本

  • 分析CCTG辅助乳腺癌试验数据,包括化疗试验MA.5和MA.21、内分泌治疗试验MA.12、MA.14和MA.27、曲妥珠单抗试验HERA/MA.24;主要目标为5年界标时BMI变化对无乳腺癌间期(BCFI)的影响。

主要发现

  • 绝经前/围绝经/绝经早期化疗试验(N=2793)中,基线BMI不影响任何终点,5年后BMI较基线增加对BCFI无显著影响(P=0.85),但1年后与更差BCFI相关(P=0.03)和DSS相关(P=0.07),3年和5年BMI增加与更好DSS相关(P=0.01;0.01)和OS相关(P=0.003;0.05)。
  • 绝经前内分泌治疗试验MA.12(N=672)中,较高基线BMI患者1年后BCFI更差(P=0.02),1年和5年后DSS更差(P=0.05;0.004),5年后OS更差(P=0.01);BMI增加5年后对BCFI无影响(P=0.90),但1年后与更差BCFI相关(P=0.01)。
  • 绝经后内分泌治疗试验MA.14和MA.27(N=8236)中,基线BMI对任何终点均无显著影响;BMI变化1年或3年后对BCFI或DSS无影响,但1年后平均BMI增加0.3与更好OS相关(P=0.02)。
  • 曲妥珠单抗治疗(N=1395)中,基线BMI和BMI变化对结局均无显著影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. METHODS: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors. RESULTS: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes. CONCLUSIONS: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes. CLINICAL TRIALS NUMBERS: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Yerushalmi R, Dong B, Chapman JW, et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol. 2017. PMID: 28379421. doi:10.1093/annonc/mdx152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。